tirzepatide a1c vs Semaglutide 2026: 22% vs 15% Weight Loss Guide LLY -0.60% today as Lilly's

In people with obesity and prediabetes followed for three years in SURMOUNT-1, only 1.3% of tirzepatide-treated participants progressed to type 2 diabetes versus 13.3% on placebo

Recent FDA Guidance on Compounded GLP-1s: In October 2023, the FDA issued warnings about compounded GLP-1 medications, specifically cautioning patients to ensure theyre receiving semaglutide (the actual FDA-approved ingredient) rather than semaglutide salts, which have different properties

Most cash-pay clinics make live visits an upsell

Access patterns differ as well

In doing so, they translate complex algorithmic reasoning into clinically meaningful insights